My Companies
Notification
Account
Log Out
Login
Sun Pharma agreed to extend Most Favored Nation pricing to U.S. state Medicaid programs and future innovative-medicine launches, while securing a delay of Section 232 tariffs on innovative pharmaceutical products for more than two years; other terms remain confidential.
Sun Pharma Board To Consider Rs15,000 Crore NCD Issuance October 12
Sun Pharma Licenses Lerodalcibep From LIB Therapeutics For Ex-US China Markets
Sun Pharma Wins Favorable Lipitor Antitrust Ruling In US Appeal